We delve into the implications of the recent study published in JAMA Internal Medicine, exposing how older risk models overestimate cardiovascular risk by about 50%. This overestimation has profound implications for primary statin use, insurer policies, and regulatory practices. Our discussion highlights the need for updated guidelines that reflect the most current evidence, ensuring better patient care and aligning clinical practice with the latest scientific findings. The GameChangerAd...